A new study has found that the speed of clinical deterioration in patients with Parkinson's disease my be influenced by different varieties of a-synuclein gene and its interaction with the microtubule-associated protein tau (MAPT) H1 haplotype. According to Yue Huang and her team from the University of New South Wales, Sydney, Australia, Parkinson's disease is marked by the abnormal accumulation of a-synuclein NACP-Rep1 and the early loss of dopamine neurons in the substantia nigra region of the brain.
A polymorphism in the promotor of NACP-Rep1 has been implicated as a risk factor for the disease.
"Our data are the first to show that polymorphisms of NACP and MAPT interact to influence the rate of progression of Parkinson's disease, a finding with clinical utility," Huang said.
"Our study shows that genotypes for NACP and MAPT can be used as a surrogate marker for the estimated rate of Parkinson's disease progression, with positive predictive values of 94-100 percent for certain genotypes," she said.
123 patients with Parkinson's disease underwent genetic testing to determine NACP-Rep 1 and MAPT H1 allele or genotype. The patient's disease severity was measured using the Unified Parkinson's Disease Rating Scale (UPDRS), and a measurement of disease progression was calculated based on detailed information about disease and symptom onset.
Three common variations, or alleles, of NACP-Rep1 were detected. Patients with one '0' NACP-Rep1 allele had significantly slower disease progression compared to two or no '0' carriers.
The results of the study showed that a low relative risk for rapid clinical progression in patients with one NACP-1 '0' allele, or those carrying MAPT non-H1H1 genotype with two NACP-Rep1 '0's. In contrast there was a high risk of a fast clinical progression in patients carrying MAPT H1H1 genotype with two or no NACP-Rep1 '0's.
"However, our results suggest that low a-synuclein expression may also be as detrimental in people with high tau expression levels, calling into question the concept that reducing neuronal a-synuclein in all PD patients may be therapeutically advantageous," she added.